What are the treatment options for an older adult with low Dehydroepiandrosterone (DHEA) levels?

Low DHEA Levels in Older Adults: Treatment Approach

Direct Recommendation

DHEA supplementation is not recommended as standard treatment for older adults with low DHEA levels, as current evidence shows minimal to no clinically meaningful benefits for cognition, physical function, energy, or overall well-being. 1, 2

---

Evidence Quality and Limitations

The available evidence for DHEA supplementation in older adults is fundamentally weak:

• Short trial durations (maximum 1 year) and small sample sizes (maximum 280 participants) severely limit conclusions about efficacy and long-term safety 2
• Cochrane systematic review found no support for improvement in memory or cognitive function following DHEA treatment, with cognitive outcomes only measured in short-duration trials of 2 weeks or less 1
• The longest-duration trial (3 months) reported subjective improvements in well-being using crude, open-ended questionnaires (67% of men, 82% of women), but this was not validated with standardized assessment tools 1

---

Limited Evidence for Specific Populations

Older Women (>70 years)

• Bone turnover showed selective improvement in women over 70 years old, with decreased osteoclastic activity measured by DEXA 3
• Libido parameters increased significantly in women over 70 years old receiving DHEA 50 mg daily for one year 3
• Skin status improved in women, including hydration, epidermal thickness, sebum production, and pigmentation 3

Functional and Psychological Correlations

• Lower baseline DHEAS levels in women correlated with functional limitations, confinement, dyspnea, depressive symptoms, poor subjective health perception, and decreased life satisfaction 4
• In men (but not women), lower DHEAS was significantly associated with increased short-term mortality at 2 and 4 years 4
• Critical caveat: These are observational correlations, not evidence that DHEA supplementation reverses these outcomes 4

---

Regulatory and Safety Considerations

United States vs. Europe

• DHEA is classified as a dietary supplement in the US and sold without medical supervision in health food stores, creating a public health concern 3, 2
• In many European countries, DHEA is considered a true hormone that has not been approved for use as hormonal replacement therapy by health authorities 5

Dosing and Monitoring

• When used in clinical trials, DHEA 50 mg daily for one year did not cause harmful accumulation of DHEAS or active steroids 3
• Small increases in testosterone and estradiol were noted, particularly in women, which may explain some physiological effects 3
• The recommended dose differs by sex in some commercial preparations (50 mg/day for men, 25 mg/day for women), but the scientific basis for this recommendation requires further exploration 1

---

Clinical Algorithm for Addressing Low DHEA

Step 1: Identify the Underlying Concern

• If the patient has sexual dysfunction (decreased libido, erectile dysfunction): Measure morning testosterone levels (8-10 AM) on two separate occasions, not DHEA 6, 7
• If the patient has osteopenia/osteoporosis: Consider testosterone replacement if hypogonadism is confirmed, as testosterone significantly increases spine bone mineral density 8
• If the patient has nonspecific symptoms (fatigue, low energy, poor well-being): Explain that DHEA supplementation has not demonstrated clinically meaningful benefits for these complaints 1, 2

Step 2: Rule Out Treatable Conditions

• Evaluate for hypothyroidism, anemia, vitamin D deficiency, sleep disorders, depression, and metabolic syndrome before attributing symptoms to low DHEA 6
• In men with sexual symptoms, measure testosterone, LH, FSH, and prolactin to distinguish primary from secondary hypogonadism 6, 7

Step 3: Set Realistic Expectations

• Explain that DHEA does not create "supermen/women" and normalizes only some effects of aging without producing dramatic improvements 3
• Clarify that current evidence does not support DHEA for cognitive enhancement, physical performance, or mood improvement 1, 2

---

When DHEA Might Be Considered (Off-Label)

If a patient insists on a trial despite lack of strong evidence:

• Target population: Women over 70 years old with osteopenia and decreased libido 3
• Dose: 50 mg daily orally 3
• Duration: Minimum 3-6 months to assess response 1, 3
• Monitoring: Assess bone turnover with DEXA at 12 months, monitor for androgenic side effects (acne, hirsutism), and measure testosterone/estradiol levels to avoid excessive conversion 3
• Discontinuation criteria: No improvement in target symptoms after 6 months 1

---

Critical Pitfalls to Avoid

• Do not recommend DHEA for cognitive enhancement, as no evidence supports this indication 1, 2
• Do not assume low DHEA causes symptoms simply because levels decline with age—this is a normal physiological process, not necessarily a disease requiring treatment 2, 4
• Do not ignore testosterone deficiency in men with sexual symptoms by focusing on DHEA instead 6, 7
• Do not prescribe DHEA long-term without clear evidence of benefit, as long-term safety data beyond one year are lacking 2

---

Future Research Needs

• High-quality trials with duration exceeding 2 weeks, large sample sizes, validated outcome measures for mood and well-being, and objective cognitive function tests are urgently needed 1
• Studies in clinical depression and Alzheimer's disease have been completed in the US but results are not yet available for review 1
• Ongoing trials in France and the US in normal elderly populations may provide additional evidence 1